1. Home
  2. HTBK vs ORKA Comparison

HTBK vs ORKA Comparison

Compare HTBK & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTBK
  • ORKA
  • Stock Information
  • Founded
  • HTBK 1997
  • ORKA 2004
  • Country
  • HTBK United States
  • ORKA United States
  • Employees
  • HTBK N/A
  • ORKA N/A
  • Industry
  • HTBK Major Banks
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • HTBK Finance
  • ORKA Health Care
  • Exchange
  • HTBK Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • HTBK 517.5M
  • ORKA 429.4M
  • IPO Year
  • HTBK 1998
  • ORKA N/A
  • Fundamental
  • Price
  • HTBK $8.96
  • ORKA $10.09
  • Analyst Decision
  • HTBK Buy
  • ORKA Strong Buy
  • Analyst Count
  • HTBK 3
  • ORKA 7
  • Target Price
  • HTBK $11.33
  • ORKA $39.67
  • AVG Volume (30 Days)
  • HTBK 338.3K
  • ORKA 394.0K
  • Earning Date
  • HTBK 04-24-2025
  • ORKA 05-15-2025
  • Dividend Yield
  • HTBK 5.83%
  • ORKA N/A
  • EPS Growth
  • HTBK N/A
  • ORKA N/A
  • EPS
  • HTBK 0.68
  • ORKA N/A
  • Revenue
  • HTBK $174,083,000.00
  • ORKA N/A
  • Revenue This Year
  • HTBK $9.66
  • ORKA N/A
  • Revenue Next Year
  • HTBK $4.72
  • ORKA N/A
  • P/E Ratio
  • HTBK $13.40
  • ORKA N/A
  • Revenue Growth
  • HTBK N/A
  • ORKA N/A
  • 52 Week Low
  • HTBK $7.66
  • ORKA $5.49
  • 52 Week High
  • HTBK $11.27
  • ORKA $53.88
  • Technical
  • Relative Strength Index (RSI)
  • HTBK 48.24
  • ORKA N/A
  • Support Level
  • HTBK $8.56
  • ORKA N/A
  • Resistance Level
  • HTBK $9.27
  • ORKA N/A
  • Average True Range (ATR)
  • HTBK 0.34
  • ORKA 0.00
  • MACD
  • HTBK 0.10
  • ORKA 0.00
  • Stochastic Oscillator
  • HTBK 73.73
  • ORKA 0.00

About HTBK Heritage Commerce Corp

Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: